Lineage

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Health, Clinical Trials, AMD, Ophthalmology, City, Regenerative medicine, Research, Spinal cord, NanoString Technologies, Roche, MD, Doctor of Philosophy, Partnership, Conference, Trial of the century, Webcast, Corporate development, Beckman Research Institute, CIRM, DVM, Patient, Lineage, Geographic atrophy, Madrona Venture Group, Expense, RPE, Therapy, Delivery, G&A, Partner, Interest, Fine chemical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.
  • “The quarter was highlighted by significant milestones and data updates on our lead program,” stated Brian M. Culley, Lineage CEO.
  • Under this new agreement, Lineage will provide additional clinical, technical, training and manufacturing services that further support the ongoing advancement and optimization of the OpRegen program.
  • Interested parties may access the conference call on May 9th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Retrieved on: 
星期一, 五月 6, 2024
Biotechnology, Health, General Health, Pharmaceutical, Optical, Health Technology, Other Science, Research, Genetics, Science, Clinical Trials, AMD, Patient, Cell, MM2, Geographic atrophy, MD, Doctor of Philosophy, OCT, Lineage, Paratriathlon, Degenerative disease, RPE, Atrophy, Therapy, Visual impairment, ELM

The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .

Key Points: 
  • The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells currently in development for the treatment of GA secondary to AMD.
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

Grand Design RV Announces First Motorized RV, ‘Lineage’ Class C

Retrieved on: 
星期三, 四月 10, 2024
The Grand Design, RV, Solitude, Class, Lineage, News, Tourism

MIDDLEBURY, Ind., April 10, 2024 (GLOBE NEWSWIRE) -- Grand Design RV has announced that their highly anticipated entrance into the motorized category will start with a class C motorhome under the brand name Lineage with an anticipated launch in July.

Key Points: 
  • MIDDLEBURY, Ind., April 10, 2024 (GLOBE NEWSWIRE) -- Grand Design RV has announced that their highly anticipated entrance into the motorized category will start with a class C motorhome under the brand name Lineage with an anticipated launch in July.
  • This is the first motorized RV product from Grand Design.
  • It recognizes our relentless commitment to being both dealer centric and customer focused,” said Don Clark, President and CEO of Grand Design RV.
  • “Until now, we have not reached an audience that prefers motorized recreational vehicles.”
    In the coming months, Grand Design will share additional information on product specifics for the Class C motorhome and the expanded motorized portfolio.

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Retrieved on: 
星期一, 四月 1, 2024
Health, Stem Cells, Genetics, General Health, Research, Science, Biotechnology, Stem cell, B cell, Regenerative medicine, Agriculture, Global health, Lineage, Madrona Venture Group, Duke University, Beckman Research Institute, City, Columbia University, University, NanoString Technologies, Fierce, Doctor of Philosophy, Investment, Therapy, Microbiology, Partner, Corporate development, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
  • Most recently, Dr. Hubbert served in the leadership team at NanoString Technologies .
  • “We are excited to add such a talented executive to our management team in the newly created position of VP Corporate Development.
  • Dr. Hubbert’s decades of experience in cell therapy, strategic investment, and partnering make her a valuable and welcome addition to the Lineage team,” stated Brian M. Culley, CEO.

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium

Retrieved on: 
星期一, 三月 18, 2024
Health, Stem Cells, Genetics, Research, Science, Biotechnology, Organization, Cell, Regenerative medicine, Caregiver, Paralysis, Lineage, Quality of life, Clinical trial, Therapy, Multimedia, SCI, Human, Person, Pharmaceutical industry

The 2nd SCIIS builds upon a successful inaugural event held on June 29, 2023, and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).

Key Points: 
  • The 2nd SCIIS builds upon a successful inaugural event held on June 29, 2023, and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).
  • The 2nd SCIIS will be held on June 26 and 27, 2024 at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
  • "Our aim at Lineage is to improve recovery and mobility by replacing the cells which are destroyed following a spinal cord injury.
  • This event will bring together both public and private companies developing new treatment options for people with spinal cord injury, alongside leaders in the spinal cord injury medical and advocacy communities.

Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

Retrieved on: 
星期二, 二月 13, 2024
Research, Neurology, FDA, Clinical Trials, Stem Cells, Biotechnology, Pharmaceutical, Health, Science, Oncology, SCI, Spinal cord, Regenerative medicine, Person, Proposition 71, CIRM, Delivery, Injury, Quality of life, Food, Surgeon, Spine, Safety, Inda, Therapy, Lineage, Patient, Journal, Ventilation, Trial of the century, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1 , an investigational allogeneic oligodendrocyte progenitor cell transplant for the treatment of spinal cord injury (SCI).

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1 , an investigational allogeneic oligodendrocyte progenitor cell transplant for the treatment of spinal cord injury (SCI).
  • The clearance of our INDa and the initiation of OPC1 clinical testing under our sponsorship represents a significant milestone for this program, and reflects our commitment to developing modern cell therapy product candidates,” stated Brian M. Culley, Lineage CEO.
  • We believe these improvements can lead to a safer surgical procedure for surgeons and patients.
  • The data from the Phase 1/2a clinical study of OPC1 in subacute cervical SCI is available here and the data from the Phase 1 clinical study of OPC1 in acute thoracic SCI is available here .

Sanctuary, Self-Care and Sustainability Drive Exterior Design in 2024

Retrieved on: 
星期二, 一月 16, 2024
Lineage, Family, Pinterest, WINCHESTER, Lighting, Privacy, Wood, Social media, Sleep, Health, Life, Knowledge, Electricity, Garden furniture, Friends, Fatigue, Freedom, ESG, DIY, Anxiety, Environment, Skin, Human, Meditation, Trex, Walt Disney, System, Marketing, Light, Nature, Xeriscaping, Yoga

Creating a restorative backyard retreat can be as simple as turning a cozy corner into a reading nook by adding plush cushions and pillows.

Key Points: 
  • Creating a restorative backyard retreat can be as simple as turning a cozy corner into a reading nook by adding plush cushions and pillows.
  • From Benjamin Moore ® to Valspar ® , the color experts have made their predictions for 2024 and nature-inspired hues are set to dominate home décor both inside and out.
  • From surfaces to furnishings and décor, outdoor design for 2024 is all about leaving a lighter environmental footprint.
  • Made from up to 95% recycled plastic film and reclaimed industrial wood scrap, Trex composite decking leads the category in sustainability.

Lineage Joins Newly Formed Global Coalition Pioneering Sustainable and Safe Frozen Food Solutions Alongside DP World and Other Supply Chain Organizations

Retrieved on: 
星期四, 十二月 7, 2023
Other Transport, Food, Beverage, Trucking, Rail, Maritime, Environment, Retail, Transport, Sustainability, REIT, Supply Chain Management, Logistics, Other Energy, Construction & Property, Energy, Climate Change, Supermarket, Public Transport, Carbon, Arnold Peter Møller, Research, Safety, Climate change, Organization, Mediterranean Shipping Company, CMA, CMA CGM, International Institute of Refrigeration, Ocean Network Express, Daikin, University, Move, DP World, DP, MSC, Food safety, London South Bank University, Temperature, Renewable energy, Lineage, Maersk

Lineage (the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today announced its coalition membership of the “Join the Move to -15 C” initiative in conjunction with global logistics firm and principal partner in COP28, DP World, among other global supply chain and logistics organizations.

Key Points: 
  • Lineage (the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today announced its coalition membership of the “Join the Move to -15 C” initiative in conjunction with global logistics firm and principal partner in COP28, DP World, among other global supply chain and logistics organizations.
  • The campaign will explore the potential transition to new, greener standards to help reduce carbon emissions in the sector on a global scale.
  • Lineage is dedicated to exploring advancements in the field to drive sustainable practices while adhering to science-backed food safety protocols.
  • The “Join the Move to –15 C” coalition and DP World have made the research accessible to all and invited stakeholders, industry leaders, and interested parties to show support for the campaign.

Lineage Bolsters Presence in Europe with New Regional Headquarters Unveiling in Warsaw, Poland

Retrieved on: 
星期五, 十一月 24, 2023
Retail, Finance, Trucking, Supply Chain Management, Rail, Commercial Building & Real Estate, Professional Services, Construction & Property, Convenience Store, Transport, Supermarket, REIT, Logistics, Food, Beverage, Acquisition, Central and Eastern Europe, Multimedia, European, Region, Movement, Film industry, Lineage

Lineage , one of the world’s leading temperature-controlled industrial REITs and integrated solutions providers, today opened its new Central Eastern European Headquarters in Warsaw, Poland.

Key Points: 
  • Lineage , one of the world’s leading temperature-controlled industrial REITs and integrated solutions providers, today opened its new Central Eastern European Headquarters in Warsaw, Poland.
  • “The opening of the new Warsaw office marks a significant commitment to Central Eastern Europe, and surrounding regions,” said Harld Peters, President of Lineage Europe.
  • "Our office in Warsaw reflects Poland's pivotal role as the gateway to Central Eastern Europe and a crucial market for produce movement in Europe,” highlighted Daniel Chudzik, Regional Vice President Operations, Central & Eastern Europe at Lineage.
  • Presently, Lineage operates a robust network of over 70 cold chain facilities in 11 countries in Europe, including six facilities in Poland.

Lineage Celebrates Grand Opening of Houston ColdPort Facility

Retrieved on: 
星期二, 十一月 14, 2023
Construction & Property, Supermarket, Supply Chain Management, Food, Beverage, REIT, Logistics, Transport, Retail, Western United States, Entrepreneurship, Congestion, ARCO, Houston Ship Channel, Port Houston, Harbor, Lineage

Lineage (the “Company”), one of the leading temperature-controlled industrial REIT and integrated solutions providers worldwide, today celebrated the grand opening of its newest facility in Houston, Texas.

Key Points: 
  • Lineage (the “Company”), one of the leading temperature-controlled industrial REIT and integrated solutions providers worldwide, today celebrated the grand opening of its newest facility in Houston, Texas.
  • Houston ColdPort is strategically located near the Jacintoport Terminal at Port Houston, a leader for the Houston Ship Channel and an integral component of Houston’s international trade activity.
  • Leaders from Lineage, Boomerang Interests, ARCO Design/Build and the Houston Port Authority gathered this morning to celebrate the grand opening of the facility during a ribbon-cutting ceremony.
  • I also want to extend a special thank you to Boomerang Interests and Lineage for allowing us to be part of this incredible project.”
    The Houston ColdPort facility began operating in October 2023.